Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News

Cannabis Shares
Blazing it? How the top ASX cannabis shares performed in FY21

Cannabis Shares
Why the Zelira (ASX:ZLD) share price is storming 7% higher

Cannabis Shares
Zelira (ASX:ZLD) share price falls despite strong trading update

Share Market News
What will Elite Cannabinoids mean for ASX cannabis shares?

Cannabis Shares
CBD to be sold in pharmacies, ASX cannabis shares react

Share Market News
The sector that’ll grow 480% this year, expert says

Best Shares
5 top ASX cannabis shares in 2020

Share Market News
Here’s why the Zelira (ASX:ZLD) share price just rocketed to a new high
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd (ASX: ZLD) is a leading global therapeutic medicinal cannabis company with access to the world’s fastest growing cannabis markets. Formerly Zelda Therapeutics, Zelira owns a portfolio of proprietary products and a pipeline of candidates undergoing clinical development.
The company focus is on developing branded cannabis products for the treatment of a variety of medical conditions, including insomnia, autism and opioid reduction. Zelira has launched two proprietary formulations under the HOPE brand for autism in multiple US-states with plans to expand into global markets in 2020.
ZLD Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
17 May 2022 | $1.38 | $0.21 | 17.87% | 21,309 | $1.18 | $1.40 | $1.18 |
16 May 2022 | $1.18 | $-0.09 | -7.14% | 10,800 | $1.26 | $1.30 | $1.18 |
13 May 2022 | $1.26 | $-0.02 | -1.56% | 9,589 | $1.28 | $1.29 | $1.26 |
12 May 2022 | $1.28 | $0.00 | 0.00% | 7,674 | $1.29 | $1.29 | $1.27 |
11 May 2022 | $1.28 | $-0.01 | -0.78% | 15,063 | $1.29 | $1.29 | $1.25 |
10 May 2022 | $1.29 | $-0.01 | -0.77% | 7,409 | $1.30 | $1.35 | $1.28 |
09 May 2022 | $1.30 | $0.02 | 1.56% | 6,268 | $1.28 | $1.30 | $1.28 |
06 May 2022 | $1.28 | $-0.12 | -8.60% | 10,782 | $1.36 | $1.40 | $1.25 |
05 May 2022 | $1.40 | $-0.05 | -3.45% | 17,645 | $1.35 | $1.40 | $1.25 |
04 May 2022 | $1.45 | $-0.07 | -4.61% | 17,947 | $1.50 | $1.50 | $1.45 |
03 May 2022 | $1.52 | $-0.20 | -11.63% | 28,909 | $1.72 | $1.72 | $1.50 |
02 May 2022 | $1.72 | $-0.28 | -14.00% | 7,965 | $1.97 | $1.97 | $1.70 |
29 Apr 2022 | $2.00 | $-0.11 | -5.21% | 14,026 | $2.10 | $2.10 | $1.96 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
03 Feb 2022 | Osagie Imasogie | Buy | 58 | $1,641,954 |
Conversion of securities.
|
03 Feb 2022 | Osagie Imasogie | Exercise | 58 | $1,641,954 |
Conversion of securities. 58,641,228 performance rights
|
03 Feb 2022 | Harry Karelis | Buy | 6 | $175,000 |
Conversion of securities.
|
03 Feb 2022 | Lisa Gray | Exercise | 58 | $1,641,954 |
Conversion of securities. 58,641,228 performance rights
|
03 Feb 2022 | Harry Karelis | Exercise | 6 | $175,000 |
Conversion of securities. 6,250,000 performance rights
|
03 Feb 2022 | Lisa Gray | Buy | 58 | $1,641,954 |
Conversion of securities.
|
03 Feb 2022 | Oludare Odumosu | Buy | 17 | $491,633 |
Conversion of securities.
|
03 Feb 2022 | Oludare Odumosu | Exercise | 17 | $491,633 |
Conversion of securities. 17,558,328 performance rights
|
17 Nov 2021 | Jason Peterson | Expiry | 8 | $304,000 |
Options expired.
|
17 Nov 2021 | Harry Karelis | Expiry | 6 | $228,000 |
Options expired.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate has over 15 years' of experience and provides accounting, secretarial and corporate advice to a number of private and public companies.
|
Dr Oludare Odumosu | Managing Director | Dec 2019 |
Dr Odumosu spent 10 years in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a combination of experiences from several academic, public health and life science organisations. In his recent role as Ilera Healthcare's first Chief Operating Officer, Dr Odumosu led the design, implementation and management of Ilera's business operation's post license award in 2017 through successful, market entry, product commercialization to profitability in 2018. He was also responsible for oversight and management of day to day operation of Ilera's vertically integrated grow/processor, wholesale and dispensary. In the same capacity, He led the formulation of Ilera proprietary cannabinoid-based product. His transition to Chief Scientific Officer/EVP Pharmaceutical Division resulted in a series of product development partnerships and the successful creation of Ilera Therapeutics. Dr Odumosu is World Bank Institute Certified public health professional.
|
Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualised and established GlaxoSmithKline Ventures and was its founding Vice President. Mr. Imasogie has held senior legal, commercial and R&D positions within pharmaceutical companies such as GSK, SmithKline, DuPont Merck and Endo, where he was the founding General Counsel and SVP for Corporate Development. Osagie has also been a Price Waterhouse Corporate Finance Partner as well as a practicing attorney with a leading US Law Firm. He is also Trustee of the University of Pennsylvania, a member of the Executive Committee and former Chairman of the Budget & Finance Committee of the University. He is Chairman of the Board of the University of Pennsylvania Law School - Adjunct Professor of Law.
|
Ms Lisa Gray | Non-Executive Director | Dec 2019 |
Ms Gray has experience in finance, marketing, business development, and operations primarily within the pharmaceutical industry. Lisa was Co-Founder and Vice Chair of Ilera Healthcare, a vertically integrated Grower, Processor and Dispenser of Medicinal Marijuana in Pennsylvania, and was a lead on the sale of this business. Lisa is also the Co-Founder and Managing Partner of PIPV Capital, a Private Equity firm focused on building companies in life sciences, where she manages the financial aspects of the firm and portfolio, generates and leads investments, manages investor communications, and acts as Board Member CEO, CFO, and/or plays various management roles, as necessary, for portfolio companies. Lisa has previously served as COO for GlaxoSmithKline (GSK) Pharmaceuticals Ventures, a pharmaceutical venture fund, as well as other operations and transactions roles over 13 years with GSK. Prior to joining GSK, Lisa was a management consultant and auditor with Coopers & Lybrand.
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
No Top 20 Shareholder Information | 0 | 0.00% |